– ISRAEL, Petah Tikva – Can-Fite BioPharma Ltd. (NYSE: CANF | TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that bind specifically to the A3 adenosine receptor, addressing cancer, liver and inflammatory diseases, today announced that Golan Bitton, CEO of Univo Pharmaceuticals (TASE: UNVO), was elected as a board member to Can-Fite at its recent annual general meeting.
“We welcome Golan as a board member and trust that his skills will be highly valuable to Can-Fite and also strengthen the collaboration in the cannabis arena, which is intended to lead to new intellectual property and novel pharmaceutical products,” stated Can-Fite CEO Pnina Fishman.
In September 2019, Can-Fite BioPharma and Univo Pharmaceutical, a medical cannabis company, entered into a collaboration agreement to co-develop cannabis-derived pharmaceutical products based on the platform technology of Can-Fite in the fields of cancer, inflammatory, autoimmune, and metabolic diseases.
Golan Bitton has many years of managerial experience in the Israeli Ministry of Defense. During his tenure there, he Implemented and managed multi-million dollar projects for the Israeli Government. Golan holds a B.A. in Economics and Business Management from Max Stern Academic College and Computer Engineering from Negev University. Golan is the founder of Univo Pharmaceuticals and is considered today as one of the leading worldwide experts in the cannabis arena.
Can-Fite is uniquely positioned to contribute its deep pharmaceutical development expertise to the medical cannabis market, based on findings published in peer-reviewed scientific journals, that demonstrate CBDs also bind to the A3 adenosine receptor, which is over-expressed in pathological cells. A3AR is a target that Can-Fite believes can be used as a predictor and selector for the use of each type of CBD and more cannabinoids in the treatment of specific diseases. Can-Fite is a global leader in the research and development of drugs that target A3AR.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. is an advanced clinical-stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction. The Company’s lead drug candidate, Piclidenoson, is currently in Phase III trials for rheumatoid arthritis and psoriasis. Can-Fite’s liver cancer drug, Namodenoson, recently completed a Phase II trial for hepatocellular carcinoma, the most common form of liver cancer, and is in a Phase II trial for the treatment of non-alcoholic steatohepatitis. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second-line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company’s third drug candidate, has shown efficacy in the treatment of erectile dysfunction in preclinical studies and the Company is investigating additional compounds, targeting A3AR, for the treatment of sexual dysfunction. These drugs have an excellent safety profile with experience in over 1,000 patients in clinical studies to date.
For more information: http://www.canfite.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
